US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VanEck Vectors Coal ETF

94.92

0.0000

Volume:- -

Turnover:- -

Market Cap:35.12M

PE:- -

High:94.92

Open:94.92

Low:94.92

Close:94.92

Loading ...

Overview Company News Filings

Zerebro Co-founder Jeffy Yu's "Faking Death" Email Exposed: To escape ongoing harassment and threats, it was the only choice to prevent a sharp decline in the project tokens ZEREBRO and OPAIUM

Wonderland Founder Exposes Evidence: Jeffy Yu Faked His Own Death, But Is Actually Still Alive

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

0xSun spent $18,800 to buy gork, currently showing a unrealized gain of over 1000 SOL

Pendle Weekly Update: Boros Prepares for Launch, 37% of PENDLE Circulating Supply Already Locked

This is the Winter of VC, yet the Spring of KOL Agency.

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

A certain crypto KOL liquidated his position in SPX over the past 3 days, selling 9 million SPX tokens at an average price of $0.432 per token.

Farcaster Metamorphosis: a16z Spends $180M to Demolish Web3 Social

Crypto KOL Jez deposited 700,000 USDC into Hyperliquid and then went 40x long on BTC.

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Unveiling How Galaxy Digital Achieved an "Institutional Grade Harvest" in the Luna Project

WSJ: Musk's DM to Crypto Influencer Tiffany Fong Asking for Child Denied

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

CZ Responds to Liang He's Rumors: Extremely Ridiculous, KOLs Are Fond of Fabricating Related Stories to Gain Traffic

Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KOL/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KOL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","market":"US","secType":"STK","nameCN":"VanEck Vectors Coal ETF","latestPrice":94.92,"timestamp":1607979600000,"preClose":94.92,"halted":4,"volume":0,"delay":0,"floatShares":370000,"shares":370000,"eps":0,"marketStatus":"Delisted","change":0,"latestTime":"12-14 16:00:00 EST","open":94.92,"high":94.92,"low":94.92,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":94.92,"sharesOutstanding":370000,"nav":95.75227,"aum":35428340.72,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KOL\",,,,,undefined,":{"symbol":"KOL","floatShares":370000,"roa":"--","roe":"--","lyrEps":0,"shares":370000,"dividePrice":0,"high":94.92,"amplitude":0,"preClose":94.92,"low":94.92,"week52Low":54.099,"pbRate":"--","week52High":111,"institutionHeld":0,"latestPrice":94.92,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":94.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KOL\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533261924","title":"Zerebro Co-founder Jeffy Yu's \"Faking Death\" Email Exposed: To escape ongoing harassment and threats, it was the only choice to prevent a sharp decline in the project tokens ZEREBRO and OPAIUM","url":"https://stock-news.laohu8.com/highlight/detail?id=2533261924","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533261924?lang=en_us&edition=fundamental","pubTime":"2025-05-07 09:24","pubTimestamp":1746581040,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 7th, Cryptocurrency Key Opinion Leader  and Wonderland founder Daniele revealed that Jeffy Yu, co-founder of Zerebro, sent a detailed letter to an early investor. In the letter, Jeffy Yu admitted to faking his own death. He explained that due to ongoing harassment from a former partner, malicious doxxing, and online hate, he chose to \"permanently exit\" through the fabrication of a death video. He clarified that this was the only option to prevent a sharp decline in the prices of the project's tokens, $ZEREBRO and $OPAIUM. He stated that he has currently disabled all social media accounts, plans to shift focus to a music career under an anonymous identity, and emphasized that this act was not for profit. He has also informed his family and friends about his safety.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/292686","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL"],"gpt_icon":0},{"id":"2533042613","title":"Wonderland Founder Exposes Evidence: Jeffy Yu Faked His Own Death, But Is Actually Still Alive","url":"https://stock-news.laohu8.com/highlight/detail?id=2533042613","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533042613?lang=en_us&edition=fundamental","pubTime":"2025-05-07 09:05","pubTimestamp":1746579900,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 7th, Crypto KOL and Wonderland founder Daniele posted that the developer of the Zerebro project, Jeffy Yu, faked his own death. Funeral home websites, obituaries, and eulogies appeared one after another, and the entire crypto community mourned for him. However, there is now conclusive evidence indicating that he is still alive.In Daniele's open letter, the content shows that this was a carefully planned \"pseudocide exit\" scheme. The Zerebro founder admitted in the letter that this was the \"only way out\" to avoid a sharp drop in the project's token price. This event is considered the first \"pseudocide exit strategy\" to appear in cryptocurrency history.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/292683","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.HKCC","TON.USD.HKCC","CFA.SI","APT.USD.CC","TON.USD.CC","KOL"],"gpt_icon":0},{"id":"2533586036","title":"Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586036","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586036?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:00","pubTimestamp":1746446400,"startTime":"0","endTime":"0","summary":"Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in theLCA5gene. Administration of OPGx-LCA5 by subretinal injection was well toleratedby study participants. RESEARCH TRIANGLE PARK, N.C., May 05, 2025  -- Opus Genetics, Inc. , a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases  and other treatments for ophthalmic disorders , today announced one-year results from adult patients treated in the ongoing Phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented yesterday at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology , taking place May 4 – 7, 2025 in Salt Lake City, Utah. The presentation, entitled “Recovery of Cone-Mediated Vision in a Severe Ciliopathy after Gene Augmentation: One Year Results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opus-genetics-announces-presentation-opgx-120000746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IRD","BK4109","SR","BK4197","BK4139","LCA","OPGX","BK4007","KOL"],"gpt_icon":0},{"id":"2533374689","title":"GENFIT to Present Latest ACLF Research at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533374689","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533374689?lang=en_us&edition=fundamental","pubTime":"2025-05-05 13:30","pubTimestamp":1746423000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 5, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver  Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within the hepatology community.I.PostersSix posters have been accepted for presentation at EASL Congress mainly covering several of GENFIT’s assets positioned in ACLF and, including, GENFIT’s latest work on Real-World data in ACLF.ACLFPoster #1: Intraperitoneal administration of investigational drug VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosisPoster: FRI-172. Author/s: Jonel Trebicka, Arun J. Sanyal, Thierry Artzner, William Bernal, Joan Clària, Javier Fernández, Lise Lotte Gluud, Jennifer Lai, Jacqueline O’Leary, Pierre-Emmanuel Rautou, Deb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-present-latest-aclf-research-053000310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","APHP","PSC","KOL","PBC","BK4108","CCA","BK4139","GNFTF","USA"],"gpt_icon":0},{"id":"2532073761","title":"Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532073761","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532073761?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients. Event to Replace Atea’s First Quarter 2025 Earnings Conference Call; Quarterly Calls to Resume with Second Quarter 2025 Financial Results. To register for the virtual HCV KOL event, please click here.Eric Lawitz, MD is the Medical Director and VP of Research and Development at the Texas Liver Institute and Clinical Professor of Medicine at the University of Texas Health San Antonio in San Antonio, Texas, USA. He began his career by achieving","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-host-virtual-hcv-110000540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","AVIR","BK4007","BK4218","BK4181","IDSA","BK4588","KOL","HST"],"gpt_icon":0},{"id":"2532025084","title":"0xSun spent $18,800 to buy gork, currently showing a unrealized gain of over 1000 SOL","url":"https://stock-news.laohu8.com/highlight/detail?id=2532025084","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532025084?lang=en_us&edition=fundamental","pubTime":"2025-05-01 16:02","pubTimestamp":1746086520,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 1st, according to GMGN monitoring, Smart Money, and crypto KOL 0xsun.sol  has spent a total of 126.68 SOL  today to buy the Solana on-chain Meme coin gork. They have sold some of the gork to exchange for 277.91 SOL, and the remaining gork can be sold to exchange for $135,300. They are currently in a profit of over 1000 SOL.The market capitalization of GORK  is now reported to be $43.3 million, with a trading volume of $183 million in the first 11 hours since its listing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/292042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["SOL","TON.USD.CC","TON.USD.HKCC","AVAX.USD.HKCC","KOL","APT.USD.HKCC","BK4129","APT.USD.CC","BK4519","SOL.USD.HKCC"],"gpt_icon":0},{"id":"2531298267","title":"Pendle Weekly Update: Boros Prepares for Launch, 37% of PENDLE Circulating Supply Already Locked","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298267","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298267?lang=en_us&edition=fundamental","pubTime":"2025-04-30 11:00","pubTimestamp":1745982000,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 30th, Pendle released a weekly report reviewing the project's latest developments. Pendle co-creator TN Lee stated in a post that Boros will break through the limits of Pendle V","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291774","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["APT.USD.HKCC","TON.USD.CC","US7Y.BOND","BK4166","APT.USD.CC","TON.USD.HKCC","US3Y.BOND","KOL","SPAQ.U","US6M.BOND","US2Y.BOND","US10Y.BOND","US30Y.BOND","PT","US5Y.BOND","US12M.BOND"],"gpt_icon":0},{"id":"2530473239","title":"This is the Winter of VC, yet the Spring of KOL Agency.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530473239","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530473239?lang=en_us&edition=fundamental","pubTime":"2025-04-28 15:39","pubTimestamp":1745825940,"startTime":"0","endTime":"0","summary":"Writers: Jaleel Plus Six, BUBBLE, BlockBeatsEditors: Jack, Zhang Wen, BlockBeatsThis article acknowledges all interviewed agencies: Evie (JE Labs); Miko (Hyperion); Er Gou (BLOCKFOCUS); Dov, Gary, Joy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/57886","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["VC","KOL","LU0757428866.USD","LU1815336091.USD","IE00BZ199S13.USD","BK4124"],"gpt_icon":0},{"id":"2530501469","title":"Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2530501469","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530501469?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"April 28th AUA data presentation to highlight study in patients with high-gradenon-muscle invasive bladder cancer . Virtual event to be held on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 24, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader  event on Monday, April 28, 2025 at 4:30 PM ET. To register, please click here.The event will feature Boris Chertin, MD  and Yair Lotan, MD , who will join Relmada’s management to discuss topline efficacy and safety data from the Phase 2 study evaluating NDV-01 for the treatment of high-grade non-muscle invasive bladder cancer . The data will be presented at the American Urological Association meeting , on April 28, 2025 in Las Vegas, Nevada.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-host-kol-event-120000022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD","BK4181","BK4139","BK4588","HST","BK4218","BK4007","KOL","LENZ","BK4585"],"gpt_icon":0},{"id":"2529506765","title":"Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529506765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529506765?lang=en_us&edition=fundamental","pubTime":"2025-04-23 19:00","pubTimestamp":1745406000,"startTime":"0","endTime":"0","summary":"BOSTON, April 23, 2025  -- Atea Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the full results from the Phase 2 clinical study of Atea’s regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus  infection will be presented at the European Association for the Study of the Liver  Congress 2025. In addition, pharmacokinetic and safety results supporting the regimen’s profile will also be presented. The EASL Congress 2025 will take place May 7-10 in Amsterdam, Netherlands.Poster ID: TOP-251 Title: Efficacy and Safety of Bemnifosbuvir and Ruzasvir after 8 Weeks of Treatment in Patie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atea-pharmaceuticals-present-data-showcasing-110000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","DDI","SOF","KOL","PK","BK4007","BK4181","AVIR","BK4085"],"gpt_icon":0},{"id":"2529211563","title":"A certain crypto KOL liquidated his position in SPX over the past 3 days, selling 9 million SPX tokens at an average price of $0.432 per token.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529211563","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529211563?lang=en_us&edition=fundamental","pubTime":"2025-04-22 17:23","pubTimestamp":1745313780,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 22, according to Onchain Lens monitoring, a certain crypto KOL @oxvyz cleared out and sold 9 million SPX in the past 3 days, with an average sell price of $0.432.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/290731","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["KOL","TON.USD.HKCC","TON.USD.CC","APT.USD.CC","APT.USD.HKCC"],"gpt_icon":0},{"id":"2529314378","title":"Farcaster Metamorphosis: a16z Spends $180M to Demolish Web3 Social","url":"https://stock-news.laohu8.com/highlight/detail?id=2529314378","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529314378?lang=en_us&edition=fundamental","pubTime":"2025-04-22 13:17","pubTimestamp":1745299020,"startTime":"0","endTime":"0","summary":"\"Today, the Farcaster team officially announced the rebranding of the Warpcast frontend to Farcaster, somewhat betraying the frontend application developers who chose the Farcaster protocol.In fact, this renaming operation is just a small reflection of Farcaster's transformation. Since last October, the Farcaster protocol has made adjustments in product updates, strategic positioning, personnel changes, and more.One detail is that after this, developer meetings will no longer distinguish between \"Farcaster topics\" and \"Warpcast updates\" but will focus on specific overall issues such as Growth, Direct Cast,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/57856","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["BK4077","BK4534","BK4579","PMF","BK4516","TWTR","BK4508","KOL"],"gpt_icon":0},{"id":"2529396489","title":"Crypto KOL Jez deposited 700,000 USDC into Hyperliquid and then went 40x long on BTC.","url":"https://stock-news.laohu8.com/highlight/detail?id=2529396489","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529396489?lang=en_us&edition=fundamental","pubTime":"2025-04-22 10:34","pubTimestamp":1745289240,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 22, according to Onchain Lens monitoring, crypto KOL Jez (@izebel_eth) deposited 1537 MKR (approximately $2.07 million) into Aave V3 and borrowed 700,000 USDC.Subsequently, they deposited this fund into Hyperliquid and opened a BTC long position with 40x leverage.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/290667","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BTC.USD.HKCC","XBTmain","TON.USD.CC","AAVE.USD.CC","KOL","APT.USD.CC","TON.USD.HKCC","AAVE.USD.HKCC","BTCmain","APT.USD.HKCC","BTC","MKR.USD.CC"],"gpt_icon":0},{"id":"2529077948","title":"Senti Bio Participates in a Virtual Investor KOL Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529077948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529077948?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:05","pubTimestamp":1745240700,"startTime":"0","endTime":"0","summary":"Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio. SOUTH SAN FRANCISCO, Calif., April 21, 2025  -- Senti Biosciences, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the release of a Virtual Investor KOL segment featuring Stephen Strickland, MD, MSCI, leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute .As part of the segment, Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio and Dr. Strickland discussed acute myeloid leukemia , the current treatment landscape and areas of unmet need, highlighting Senti Bio’s lead program, SENTI-202, and the clinical and preclinical data released by Senti to date.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/senti-bio-participates-virtual-investor-130500129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNTI","KOL","BK4539","BK4139"],"gpt_icon":0},{"id":"2528275446","title":"Unveiling How Galaxy Digital Achieved an \"Institutional Grade Harvest\" in the Luna Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2528275446","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528275446?lang=en_us&edition=fundamental","pubTime":"2025-04-17 14:26","pubTimestamp":1744871160,"startTime":"0","endTime":"0","summary":"Original Title: \"From 'Evangelist' to 'Harvester': Galaxy's Art of 'Pump and Dump'\"Original Author: DaiiIn the world of cryptocurrency, the distance between an 'Evangelist' and a 'Harvester' is often ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/57795","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["BTC.USD.CC","BTC.USD.HKCC","KOL","UST","ETH.USD.HKCC","ETH.USD.CC"],"gpt_icon":0},{"id":"2528673949","title":"WSJ: Musk's DM to Crypto Influencer Tiffany Fong Asking for Child Denied","url":"https://stock-news.laohu8.com/highlight/detail?id=2528673949","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528673949?lang=en_us&edition=fundamental","pubTime":"2025-04-17 11:22","pubTimestamp":1744860120,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 17th, according to The Wall Street Journal, cryptocurrency KOL Tiffany Fong received interaction from Musk on X due to reporting on the FTX collapse event. As Fong released more pro-Trump political content, Musk's interaction with Fong also increased. Last summer, Musk started paying attention to her. According to screenshots shared by Tiffany Fong, during the most active period of interaction with Musk, Fong made $21,000 on the platform in a two-week period in November.According to sources familiar with the matter, Musk had directly sent a private message to Tiffany Fong asking if she was interested in having a child for him. The two had never met before.Tiffany Fong did not pursue further involvement with Musk because she desired to have a child in a more traditional nuclear family setting. However, she confided her thoughts on the matter to several friends, including St. Clair, who had also had a child for Musk. Fong was concerned that rejecting Musk would imp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/290091","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["TIF","KOL"],"gpt_icon":1},{"id":"2527492277","title":"Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492277","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492277?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ --Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader  event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles  and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET. To register, please click here.Dr. Wainberg will connect with Leap's Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab  may improve upon the current treatment landscape for previously treated patients with advanced microsatellite stable  colorectal cancer .The event will focus on reviewing the positive data from Part B of the Phase 2 DeFianCe study of sirexatamab in second-line patients with advanced MSS CRC. Sirexatamab, Leap's most advanced clinical program, is a humanize","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LPTX","HST","BK4213","BK4585","MSS","BK4181","LU0456854461.SGD","LENZ","BK4157","LU0266512127.USD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","AEIS","BK4218","BK4113","BK4588","BK4563","BK4139","CRC","BK4505","IE0031619046.USD","BK4007","KOL"],"gpt_icon":0},{"id":"2527319264","title":"CZ Responds to Liang He's Rumors: Extremely Ridiculous, KOLs Are Fond of Fabricating Related Stories to Gain Traffic","url":"https://stock-news.laohu8.com/highlight/detail?id=2527319264","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527319264?lang=en_us&edition=fundamental","pubTime":"2025-04-14 23:27","pubTimestamp":1744644420,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 14th, CZ responded on social media to Liangxi's previous statement \"CZ is working for the Federal Reserve, cooperating to harvest the world, and has never been imprisoned\" by saying: \"This is simply ridiculous. This Chinese KOL said I am working for the Federal Reserve and that I have never been to jail, how I wish this were true. Nowadays, Chinese KOLs have a saying: make up a story about Binance or CZ, and it will bring a lot of traffic. Today, this guy gained 119,000 listeners on X Spaces just based on this rumor.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/289693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["US5Y.BOND","US3Y.BOND","US7Y.BOND","US6M.BOND","KOL","US30Y.BOND","US10Y.BOND","US12M.BOND","US2Y.BOND"],"gpt_icon":0},{"id":"2526593371","title":"Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2526593371","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526593371?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288202,"startTime":"0","endTime":"0","summary":"For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.What if you'd invested in Veracyte  ten years ago?It may not have been easy to hold on to VCYT for all that time, but if you did, how much would your investment be worth today?With that in mind, let's take a look at Veracyte's main business drivers.Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Veracyte, if you","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-much-youd-invested-1000-123002034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KOL","VCYT"],"gpt_icon":0},{"id":"2525993228","title":"Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2525993228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525993228?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057520/0/en/Opus-Genetics-Announces-One-Month-Clinical-Data-from-Pediatric-Patient-in-Phase-1-2-Trial-of-OPGx-LCA5-Gene-Therapy-in-Inherited-Retinal-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","KOL","BK4023","IE00BZ1G4Q59.USD","BK4588","SAP","IE00BHPRN162.USD","IRD","LU0170899867.USD","BK4585","LU0971096721.USD","LU0149725797.USD","CMC","IE00BKVL7J92.USD","LCA","BK4613","IE00B1BXHZ80.USD","LU0267386448.USD","LU0882574139.USD","LU1363072403.SGD","BK4007","BK4528"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":93,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KOL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-12-15","symbol":"KOL","reason":null,"defaultRemindTime":1608042600000,"announcedDate":"2020-12-04","type":"delisting","dateTimestamp":1608008400000},{"market":"US","date":"2020-12-11","symbol":"KOL","amount":3.2432,"defaultRemindTime":1607697000000,"name":"Market Vectors-Coal ETF","payableDate":"2020-12-14","currency":"USD","type":"dividend","dateTimestamp":1607662800000},{"market":"US","date":"2020-04-15","symbol":"KOL","type":"split","dateTimestamp":1586923200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2019-12-23","symbol":"KOL","amount":0.939,"name":"Market Vectors-Coal ETF","payableDate":"2019-12-24","currency":"USD","type":"dividend","dateTimestamp":1577077200000},{"market":"US","date":"2018-12-20","symbol":"KOL","amount":0.824,"name":"Market Vectors-Coal ETF","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KOL\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":null,"paymentDate":null,"value":0.824,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":null,"value":0.939,"currency":"USD"},{"executeDate":"2020-12-11","recordDate":"2020-12-14","paymentDate":null,"value":3.2432,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KOL\",market:\"US\",delay:false,,,undefined,":{}}}